These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27597282)

  • 21. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
    Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
    World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential circulating miRNA signature for early detection of NSCLC.
    Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
    Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
    Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
    Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
    Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
    World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer.
    Zhang J; Han X; Gao C; Xing Y; Qi Z; Liu R; Wang Y; Zhang X; Yang YG; Li X; Sun B; Tian X
    Genomics Proteomics Bioinformatics; 2018 Jun; 16(3):187-199. PubMed ID: 30010036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
    Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
    Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
    Bordi P; Tiseo M; Rofi E; Petrini I; Restante G; Danesi R; Del Re M
    Clin Lung Cancer; 2017 Nov; 18(6):692-697. PubMed ID: 28601386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
    Hou F; Sun XD; Deng ZY
    Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
    Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
    J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
    Pyo JS; Kang G; Sohn JH
    Int J Biol Markers; 2016 Dec; 31(4):e413-e421. PubMed ID: 27338643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.
    Du YZ; Gu XH; Li L; Gao F
    J Surg Oncol; 2011 Dec; 104(7):836-40. PubMed ID: 21656524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
    PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
    Li W; Li N; Kang X; Shi K
    Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.